Literature DB >> 9142323

Vascular origin determines angiotensin I-converting enzyme expression in endothelial cells.

B Baudin1, M Berard, J L Carrier, Y Legrand, L Drouet.   

Abstract

Previous observations on the heterogeneous distribution of von Willebrand factor in the vascular endothelium led us to examine the expression of angiotensin I-converting enzyme (ACE) in function of the vascular origin of endothelial cells (EC). EC from pig thoracic aorta, pulmonary artery, inferior vena cava and brain capillaries were cultured and assayed for ACE by enzymatic radiochemical determination and by western-blot and immunofluorescence using an antiACE polyclonal antibody. EC from the various vascular levels secreted ACE in the culture medium; western-blot analysis showed its presence at cellular level and immunofluorescence confirmed its location on the plasma membrane. But quantification revealed that EC from pulmonary artery contain more ACE than EC from the other vessels, especially from brain capillaries; immunofluorescence correlated well with the functional data. In contrast, secretion of ACE by brain capillaries EC was faster than that of arteries and of vena cava, the latter being the less effective. This differential ACE expression along the vascular tree could have a pharmacological implication since ACE inhibitors, used in the treatment of arterial hypertension, may act more at the vascular level than on the plasma renin-angiotensin system. On the other hand, endothelial distribution of ACE was different from that of von Willebrand factor; in particular we showed that EC cultured from vessels of pigs homozygous for the von Willebrand disease, in which von Willebrand factor synthesis was completely abolished, normally express ACE.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9142323     DOI: 10.3109/10623329709044160

Source DB:  PubMed          Journal:  Endothelium        ISSN: 1026-793X


  6 in total

1.  Phenotypic and functional characteristics of porcine peritoneal mesothelial cells.

Authors:  J Ohan; M A Gilbert; J P Brouland; J P Rougier; G Trugnan; M Wassef; G Leseche; L Drouet
Journal:  In Vitro Cell Dev Biol Anim       Date:  1999 Nov-Dec       Impact factor: 2.416

2.  [Angiotensin converting enzyme (ACE, CD143) in the regular pulmonary vasculature].

Authors:  A M Müller; K Gruhn; S Lange; F E Franke; K-M Müller
Journal:  Pathologe       Date:  2004-03       Impact factor: 1.011

3.  ACE inhibition enhances bradykinin relaxations through nitric oxide and B1 receptor activation in bovine coronary arteries.

Authors:  Kathryn M Gauthier; Cody J Cepura; William B Campbell
Journal:  Biol Chem       Date:  2013-09       Impact factor: 3.915

4.  Role of a Novel Silver Fir (Abies alba) Extract, Abigenol®/AlbiPhenol®, in Modulating Cardiovascular Disorders: Key Factors.

Authors:  Kevin Leone; Marta Micheletto; Giovanni Di Maira; Erik Tedesco; Federico Benetti; Urška Zaloker
Journal:  Antioxidants (Basel)       Date:  2022-03-23

Review 5.  A Review of the Role of Bradykinin and Nitric Oxide in the Cardioprotective Action of Angiotensin-Converting Enzyme Inhibitors: Focus on Perindopril.

Authors:  Arnaud Ancion; Julien Tridetti; Mai-Linh Nguyen Trung; Cécile Oury; Patrizio Lancellotti
Journal:  Cardiol Ther       Date:  2019-10-01

Review 6.  Snake venom-derived bradykinin-potentiating peptides: A promising therapy for COVID-19?

Authors:  Ahmed S Gouda; Bruno Mégarbane
Journal:  Drug Dev Res       Date:  2020-08-05       Impact factor: 5.004

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.